Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EBT (2016 - 2025)

Viking Therapeutics' EBT history spans 12 years, with the latest figure at -$157.7 million for Q4 2025.

  • For Q4 2025, EBT fell 345.56% year-over-year to -$157.7 million; the TTM value through Dec 2025 reached -$359.6 million, down 227.0%, while the annual FY2025 figure was -$359.6 million, 227.0% down from the prior year.
  • EBT for Q4 2025 was -$157.7 million at Viking Therapeutics, down from -$90.8 million in the prior quarter.
  • Across five years, EBT topped out at -$12.4 million in Q4 2021 and bottomed at -$157.7 million in Q4 2025.
  • The 5-year median for EBT is -$20.9 million (2022), against an average of -$34.0 million.
  • The largest annual shift saw EBT fell 10.44% in 2023 before it tumbled 345.56% in 2025.
  • A 5-year view of EBT shows it stood at -$12.4 million in 2021, then tumbled by 58.29% to -$19.6 million in 2022, then dropped by 25.72% to -$24.6 million in 2023, then tumbled by 44.0% to -$35.4 million in 2024, then plummeted by 345.56% to -$157.7 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's EBT are -$157.7 million (Q4 2025), -$90.8 million (Q3 2025), and -$65.5 million (Q2 2025).